Top

Published in:

01-06-2019 | Melanoma | Original Article

SOX10 expression in mammary invasive ductal carcinomas and benign breast tissue

Authors: Kenrry Chiu, Diana N. Ionescu, Malcolm Hayes

Published in: Virchows Archiv | Issue 6/2019

Abstract

SOX10 immunohistochemistry is used to identify tumors of neural crest origin, including melanocytic neoplasms. SOX10 expression has also been identified in myoepithelial cells of the breast and in a subset of invasive mammary carcinomas. In order to characterize SOX10 expression in ductal carcinomas of the breast, the aim of this study was to characterize the SOX10 in invasive ductal carcinomas according to molecular subtype, DCIS, and benign breast tissue. Forty cases of invasive ductal carcinoma of the breast were retrieved, with ten cases with immunohistochemical profile compatible with luminal A-like, luminal B-HER2-positive, non-luminal HER2-positive, and triple-negative subtypes. Whole tissue sections from each case were stained with SOX10. Six (60%) of ten triple-negative tumors were SOX10+ compared with 1 (3%) of 30 carcinomas of other molecular subtypes. All but one of the positive tumors showed at least moderate expression in at least 40% of tumor cells. All seven cases SOX10+ carcinomas were grade 3 tumors. Of the 13 cases with DCIS available for assessment, one (8%) showed positive SOX10 expression (a case associated with triple-negative carcinoma). Twenty-two cases contained normal breast tissue that showed SOX10 expression in both myoepithelial and luminal cells, predominantly patchy with variable intensity. SOX10 showed incomplete myoepithelial staining compared to other myoepithelial markers. In conclusion, SOX10 IHC cannot reliably differentiate between high-grade triple-negative carcinomas, melanomas, and myoepithelial tumors in the breast. SOX10 is not as robust a myoepithelial marker compared with other established markers.

Nonaka D, Chiriboga L, Rubin BP (2008) SOX10: a pan-schwannian and melanocytic marker. Am J Surg Pathol 32(9):1291–1298. https://doi.org/10.1097/PAS.0b013e3181658c14 CrossRefPubMed

Fufa TD, Harris ML, Watkins-Chow DE, Levy D, Gorkin DU, Gildea DE, Song L, Safi A, Crawford GE, Sviderskaya EV, Bennett DC, McCallion AS, Loftus SK, Pavan WJ (2015) Genomic analysis reveals distinct mechanisms and functional classes of SOX10-regulated genes in melanocytes. Hum Mol Genet 24(19):5433–5450. https://doi.org/10.1093/hmg/ddv267 CrossRefPubMedPubMedCentral

Kuhlbrodt K, Herbarth B, Sock E, Hermans-Borgmeyer I, Wegner M (1998) SOX10, a novel transcriptional modulator in glial cells. J Neurosci 18(1):237–250CrossRefPubMed

Pusch C, Hustert E, Pfeifer D, Sudbeck P, Kist R, Roe B, Wang Z, Balling R, Blin N, Scherer G (1998) The SOX10/SOX10 gene from human and mouse: sequence, expression, and transactivation by the encoded HMG domain transcription factor. Hum Genet 103(2):115–123. https://doi.org/10.1007/s004390050793 CrossRefPubMed

Karamchandani JR, Nielsen TO, van de Rijn M, West RB (2012) SOX10 and S100 in the diagnosis of soft-tissue neoplasms. Appl Immunohistochem Mol Morphol 20(5):445–450. https://doi.org/10.1097/PAI.0b013e318244ff4b CrossRefPubMed

Miettinen M, McCue PA, Sarlomo-Rikala M, Biernat W, Czapiewski P, Kopczynski J, Thompson LD, Lasota J, Wang Z, Fetsch JF (2015) SOX10--a marker for not only schwannian and melanocytic neoplasms but also myoepithelial cell tumors of soft tissue: a systematic analysis of 5134 tumors. Am J Surg Pathol 39(6):826–835. https://doi.org/10.1097/PAS.0000000000000398 CrossRefPubMedPubMedCentral

Mohamed A, Gonzalez RS, Lawson D, Wang J, Cohen C (2013) SOX10 expression in malignant melanoma, carcinoma, and normal tissues. Appl Immunohistochem Mol Morphol 21(6):506–510. https://doi.org/10.1097/PAI.0b013e318279bc0a CrossRefPubMed

Ordonez NG (2013) Value of SOX10 immunostaining in tumor diagnosis. Adv Anat Pathol 20(4):275–283. https://doi.org/10.1097/PAP.0b013e318297a9d0 CrossRefPubMed

Shin J, Vincent JG, Cuda JD, Xu H, Kang S, Kim J, Taube JM (2012) SOX10 is expressed in primary melanocytic neoplasms of various histologies but not in fibrohistiocytic proliferations and histiocytoses. J Am Acad Dermatol 67(4):717–726. https://doi.org/10.1016/j.jaad.2011.12.035 CrossRefPubMed

10.

Hsieh MS, Lee YH, Chang YL (2016) SOX10-positive salivary gland tumors: a growing list, including mammary analogue secretory carcinoma of the salivary gland, sialoblastoma, low-grade salivary duct carcinoma, basal cell adenoma/adenocarcinoma, and a subgroup of mucoepidermoid carcinoma. Hum Pathol 56:134–142. https://doi.org/10.1016/j.humpath.2016.05.021 CrossRefPubMed

11.

Ivanov SV, Panaccione A, Nonaka D, Prasad ML, Boyd KL, Brown B, Guo Y, Sewell A, Yarbrough WG (2013) Diagnostic SOX10 gene signatures in salivary adenoid cystic and breast basal-like carcinomas. Br J Cancer 109(2):444–451. https://doi.org/10.1038/bjc.2013.326 CrossRefPubMedPubMedCentral

12.

Ohtomo R, Mori T, Shibata S, Tsuta K, Maeshima AM, Akazawa C, Watabe Y, Honda K, Yamada T, Yoshimoto S, Asai M, Okano H, Kanai Y, Tsuda H (2013) SOX10 is a novel marker of acinus and intercalated duct differentiation in salivary gland tumors: a clue to the histogenesis for tumor diagnosis. Mod Pathol 26(8):1041–1050. https://doi.org/10.1038/modpathol.2013.54 CrossRefPubMed

13.

Tacha D, Qi W, Ra S, Bremer R, Yu C, Chu J, Hoang L, Robbins B (2015) A newly developed mouse monoclonal SOX10 antibody is a highly sensitive and specific marker for malignant melanoma, including spindle cell and desmoplastic melanomas. Arch Pathol Lab Med 139(4):530–536. https://doi.org/10.5858/arpa.2014-0077-OA CrossRefPubMed

14.

Cimino-Mathews A, Subhawong AP, Elwood H, Warzecha HN, Sharma R, Park BH, Taube JM, Illei PB, Argani P (2013) Neural crest transcription factor Sox10 is preferentially expressed in triple-negative and metaplastic breast carcinomas. Hum Pathol 44(6):959–965. https://doi.org/10.1016/j.humpath.2012.09.005 CrossRefPubMed

15.

Harbhajanka A, Chahar S, Miskimen K, Silverman P, Harris L, Williams N, Varadan V, Gilmore H (2018) Clinicopathological, immunohistochemical and molecular correlation of neural crest transcription factor SOX10 expression in triple negative breast carcinoma. Hum Pathol 80:163–169. https://doi.org/10.1016/j.humpath.2018.06.007 CrossRefPubMed

16.

Nelson ER, Sharma R, Argani P, Cimino-Mathews A (2017) Utility of SOX10 labeling in metastatic breast carcinomas. Hum Pathol 67:205–210. https://doi.org/10.1016/j.humpath.2017.08.011 CrossRefPubMed

17.

Tang P, Tse GM (2016) Immunohistochemical surrogates for molecular classification of breast carcinoma: a 2015 update. Arch Pathol Lab Med 140(8):806–814. https://doi.org/10.5858/arpa.2015-0133-RA CrossRefPubMed

18.

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 134(6):907–922. https://doi.org/10.1043/1543-2165-134.6.907 CrossRefPubMedPubMedCentral

19.

Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF, American Society of Clinical Oncology, College of American Pathologists (2014) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med 138(2):241–256. https://doi.org/10.5858/arpa.2013-0953-SA CrossRefPubMed

20.

Cimino-Mathews A, Subhawong AP, Illei PB, Sharma R, Halushka MK, Vang R, Fetting JH, Park BH, Argani P (2013) GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas. Hum Pathol 44(7):1341–1349. https://doi.org/10.1016/j.humpath.2012.11.003 CrossRefPubMedPubMedCentral

21.

Bannykh SI, Stolt CC, Kim J, Perry A, Wegner M (2006) Oligodendroglial-specific transcriptional factor SOX10 is ubiquitously expressed in human gliomas. J Neuro-Oncol 76(2):115–127. https://doi.org/10.1007/s11060-005-5533-x CrossRef

22.

Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW (2008) Immunohistochemical characteristics of melanoma. J Cutan Pathol 35(5):433–444. https://doi.org/10.1111/j.1600-0560.2007.00891.x CrossRefPubMed

23.

Jing X, Michael CW, Theoharis CG (2013) The use of immunocytochemical study in the cytologic diagnosis of melanoma: evaluation of three antibodies. Diagn Cytopathol 41(2):126–130. https://doi.org/10.1002/dc.21791 CrossRefPubMed

24.

Dwarakanath S, Lee AK, Delellis RA, Silverman ML, Frasca L, Wolfe HJ (1987) S-100 protein positivity in breast carcinomas: a potential pitfall in diagnostic immunohistochemistry. Hum Pathol 18(11):1144–1148CrossRefPubMed

25.

Stroup RM, Pinkus GS (1988) S-100 immunoreactivity in primary and metastatic carcinoma of the breast: a potential source of error in immunodiagnosis. Hum Pathol 19(8):949–953CrossRefPubMed

26.

Peng Y, Butt YM, Chen B, Zhang X, Tang P (2017) Update on immunohistochemical analysis in breast lesions. Arch Pathol Lab Med 141(8):1033–1051. https://doi.org/10.5858/arpa.2016-0482-RA CrossRefPubMed

27.

Krings G, Nystrom M, Mehdi I, Vohra P, Chen YY (2014) Diagnostic utility and sensitivities of GATA3 antibodies in triple-negative breast cancer. Hum Pathol 45(11):2225–2232. https://doi.org/10.1016/j.humpath.2014.06.022 CrossRefPubMed

28.

Dang DN, Raj G, Sarode V, Molberg KH, Vadlamudi RK, Peng Y (2015) Significantly increased PELP1 protein expression in primary and metastatic triple-negative breast carcinoma: comparison with GATA3 expression and PELP1's potential role in triple-negative breast carcinoma. Hum Pathol 46(12):1829–1835. https://doi.org/10.1016/j.humpath.2015.07.023 CrossRefPubMed

29.

Zombori T, Cserni G (2018) Immunohistochemical analysis of the expression of breast markers in basal-like breast carcinomas defined as triple negative cancers expressing keratin 5. Pathol Oncol Res 24(2):259–267. https://doi.org/10.1007/s12253-017-0246-y CrossRefPubMed

30.

Lewis GH, Subhawong AP, Nassar H, Vang R, Illei PB, Park BH, Argani P (2011) Relationship between molecular subtype of invasive breast carcinoma and expression of gross cystic disease fluid protein 15 and mammaglobin. Am J Clin Pathol 135(4):587–591. https://doi.org/10.1309/AJCPMFR6OA8ICHNH CrossRefPubMedPubMedCentral

31.

Dewar R, Fadare O, Gilmore H, Gown AM (2011) Best practices in diagnostic immunohistochemistry: myoepithelial markers in breast pathology. Arch Pathol Lab Med 135(4):422–429. https://doi.org/10.1043/2010-0336-CP.1 CrossRefPubMed

Title: SOX10 expression in mammary invasive ductal carcinomas and benign breast tissue
Authors: Kenrry Chiu
Diana N. Ionescu
Malcolm Hayes
Publication date: 01-06-2019
Publisher: Springer Berlin Heidelberg
Keywords: Melanoma
Melanoma
Published in: Virchows Archiv / Issue 6/2019
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-019-02557-1

At a glance: The STEP trials

Springer Medicine

SOX10 expression in mammary invasive ductal carcinomas and benign breast tissue

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2019

ALK-negative anaplastic large cell lymphoma arising in the thrombus of an aortic prosthesis preceeded by clonally related lymphomatoid papulosis

In this issue

Lymphomas of the head and neck region: an update

Clinicopathological characteristics of thrombospondin type 1 domain-containing 7A-associated membranous nephropathy

Response to “Novel” nomogram and algorithm do not aid in the distinction of primary vs. metastatic mucinous carcinoma of ovary: letter to the Editor

Hormonal receptors in cutaneous vascular malformations: 51 cases